The Effect of Optive and Optive Advanced Artificial Tears on the Healthy Tear Film

ABSTRACT

Purpose: To evaluate the impact of Optive (Allergan, Irvine, CA) and Optive Advanced (Allergan, Irvine, CA) on tear film stability and quality during a one-hour observation period when compared to saline (Pfizer, Perth, WA).

Methods: This was a double-masked, cross-over study. Twenty participants attended three visits, randomly receiving either Optive, Optive Advanced or saline. Oculus Keratograph 5M (Oculus, Arlington, WA, USA), non-invasive keratograph break-up time (NIKBUT), Lipiview (TearScience Inc, Morrisville, NC, USA), lipid layer thickness (LLT) and comfort were measured prior to and 5, 15 and 60 min after drop instillation.

Results: Optive Advanced demonstrated a significant increase in LLT between baseline (57.5 ± 12.3 nm) and both 5 min (67.5 ± 18.8 nm, p = 0.04) and 15 min (68.9 ± 17.3 nm, p = 0.04) but not 60 min (61.6 ± 14.3 nm, p = 0.47). Optive and saline were not different between timepoints for LLT (p > 0.05). There was no difference between timepoints for any of the drops for NIKBUT (p = 0.75). Comfort was significantly better at 5 min compared to baseline for Optive (8.3 ± 1.2 and 7.3 ± 1.4, respectively, p = 0.03) but not different for Optive Advance or saline (p > 0.05).

Conclusions: Optive Advanced increased LLT for 15 min following instillation, returning to baseline within one hour. This did not however, translate into an improvement in tear film stability over this time period. Only Optive demonstrated an improvement in comfort.

KEYWORDS:

• Artificial tears
• lipid layer thickness
• tear film break-up time
• dry eye

Acknowledgments

The authors wish to acknowledge Mr. Daniel Tilia, A/Prof Michelle Madigan, Dr Alex Hui and Dr Lisa Asper for their assistance with drop instillation.

Declaration of Interest

This work is original, has not been published and is not being considered for publication elsewhere. There is no funding associated with this work. Dr Jacqueline Tan receives funding from Allergan, Alcon and CooperVision for other projects. Professor Minas Coroneo receives funding from Allergan for other projects. All authors have contributed significantly to the project and subsequent drafting, revising and approval of the final version submitted.

Additional information

Funding

This project did not receive research funding or contracted research funding governed by the University of New South Wales.